Newron Pharmaceuticals and EA Pharma's License Agreement
MILAN & MORRISTOWN, N.J. & TOKYO--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a notable biopharmaceutical company focused on developing innovative therapies for central and peripheral nervous system diseases, has officially partnered with EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. This partnership signifies a pivotal move in expanding the reach of Newron’s innovative modulator of glutamate release, known as Evenamide, into Japan and other specified Asian territories.
Terms of the License Agreement
Under this license agreement, Newron will obtain up to €117 million from EA Pharma. This financial arrangement includes an upfront payment of €44 million along with contributions toward a future Phase III trial that will take place outside the licensed territories, regulatory milestones, and tiered royalties that will reach up to a double-digit percentage of net sales for Evenamide.
Impact on Newron's Financial Outlook
The execution of this agreement, particularly the significant upfront payment, is anticipated to substantially enhance Newron’s financial performance in the upcoming year. Stefan Weber, CEO of Newron, expressed optimism regarding this partnership, emphasizing its role as a major step toward providing a novel, evidence-based treatment alternative for patients enduring schizophrenia, especially those who have had insufficient responses to existing treatments.
Newron's Development Goals
Weber highlighted that Newron aims to commence a Phase III one-year study focusing on treatment-resistant schizophrenia (TRS) and expects to initiate this pivotal study outside of the licensed territories by 2025. Additionally, the company is determined to explore further development pathways for Evenamide across other regions.
EA Pharma’s Vision for Evenamide
Hidenori Yabune, President of EA Pharma, noted their excitement regarding the acquisition of Evenamide’s license. He emphasized that the drug’s unique mechanism targeting glutamate regulation positions it as a revolutionary treatment for schizophrenia. The EA Pharma team believes in Evenamide’s potential to provide transformative results for patients battling this challenging condition.
Understanding Schizophrenia and Its Challenges
Schizophrenia affects approximately 25 million individuals globally. Despite the availability of over 60 antipsychotics, many patients continue to suffer from severe illness or treatment resistance. Research indicates that between 30-50% of patients may not respond effectively to existing medications. There is a stark need for solutions targeting the glutamatergic system, as traditional treatments focus mainly on dopaminergic pathways.
Evenamide's Role in Treatment
As the first new chemical entity showing significant benefits in treating hard-to-reach patient populations, Evenamide has shown promise in various clinical trials. Notably, the Phase III study 008A highlighted its efficacy when used as an add-on therapy alongside second-generation antipsychotics for patients who struggle with chronic schizophrenia.
The Results of Clinical Studies
In trials, Evenamide met crucial endpoints, demonstrating its potential effectiveness. Importantly, it showed a statistically significant increase in patients experiencing clinically meaningful benefits, all while exhibiting a favorable safety profile without the common side effects associated with typical antipsychotic medications.
Future Milestones for Evenamide Development
In the first quarter of the following year, Newron revealed the final results from study 014/015, supporting Evenamide's position as a beneficial add-on treatment. The data indicated sustained clinical benefits over the treatment period, with a notable majority of patients reporting reduced disease severity.
About Newron Pharmaceuticals
Newron Pharmaceuticals is a dedicated biopharmaceutical firm focused on pioneering therapies for various nervous system ailments. With its headquarters in Bresso near Milan, Italy, Newron has made significant strides in developing therapies for conditions such as Parkinson’s disease and is now committed to advancing Evenamide as a leading therapeutic option for schizophrenia.
About EA Pharma
EA Pharma Co., Ltd., backed by Eisai Co., Ltd., specializes in pharmaceuticals with a robust history in gastrointestinal treatments. Established through strategic integration, EA Pharma is committed to augmenting the landscape of specialty pharmaceuticals across its operational territories.
Frequently Asked Questions
What does the license agreement between Newron and EA Pharma entail?
The license agreement allows EA Pharma to develop, manufacture, and commercialize Evenamide in Japan and other Asian territories, with Newron receiving significant financial compensation.
How will this agreement affect Newron's financial outlook?
The upfront payment and anticipated milestones from this deal are expected to enhance Newron's financial position in the coming year significantly.
What is Evenamide's mechanism of action?
Evenamide modulates glutamate release, representing a novel approach to treat schizophrenia, targeting patients who are treatment-resistant or poorly responding to other medications.
What are the expected next steps for Newron regarding Evenamide?
Newron plans to initiate a Phase III trial for Evenamide focusing on treatment-resistant schizophrenia, expected to begin in 2025.
Why is there a need for new treatments for schizophrenia?
Despite numerous treatments available, many patients do not achieve adequate symptom control, highlighting the urgent need for innovative therapies like Evenamide to meet this unmet medical need.
